US FDA Drug Center Tries New Approach To Old Consistency Problems
Executive Summary
Drug developers should not expect the US FDA's new Quantitative Medicine Center of Excellence to dramatically impact the agency's long-standing problem of ensuring more consistent use of innovative regulatory approaches in application reviews.